share_log

JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $35

JMP Securities Maintains Market Outperform on Integra Lifesciences, Lowers Price Target to $35

JMP證券保持英特格拉生命科學市場優勢,將價格目標下調至35美元
Benzinga ·  07/30 11:23  · 評級/大行評級

JMP Securities analyst David Turkaly maintains Integra Lifesciences (NASDAQ:IART) with a Market Outperform and lowers the price target from $40 to $35.

JMP Securities分析師戴維·特卡利維持Integra Lifesciences(納斯達克股票代碼:IART)的市場表現跑贏大盤,並將目標股價從40美元下調至35美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論